Kymera Therapeutics, Inc.
KYMR
$30.02
$0.270.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -65.58M | -70.75M | -62.49M | -42.06M | -48.56M |
| Total Depreciation and Amortization | 2.05M | 1.99M | 1.99M | 1.94M | 1.46M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.71M | 10.53M | 11.28M | 10.32M | 13.82M |
| Change in Net Operating Assets | -27.33M | -3.55M | -971.00K | -13.13M | -6.32M |
| Cash from Operations | -79.15M | -61.78M | -50.19M | -42.94M | -39.59M |
| Capital Expenditure | -467.00K | -936.00K | 189.00K | -4.69M | -7.40M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 49.08M | 69.50M | -157.87M | 20.33M | -323.21M |
| Cash from Investing | 48.62M | 68.57M | -157.68M | 15.64M | -330.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -277.00K | -293.00K | -641.00K | -352.00K | -290.00K |
| Issuance of Common Stock | 535.00K | 31.42M | 251.56M | 1.76M | 354.05M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -28.36M | -- | -- | -- |
| Cash from Financing | 258.00K | 2.77M | 250.92M | 1.41M | 353.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.28M | 9.55M | 43.05M | -25.88M | -16.44M |